A Therapy That Returns $12 for Every Dollar: The New Economics of Treating Opioid Misuse With Mindfulness

The opioid epidemic costs the United States as much as $4 trillion a year once health care, criminal justice, and lost productivity are tallied. Against that figure, a new economic evaluation makes a strikingly simple claim: a neuroscience-informed therapy called Mindfulness-Oriented Recovery Enhancement returns about $12 in economic benefit for every $1 spent delivering it.

The analysis, published July 23 in Value in Health and led by University of Utah health economist Fernando Wilson, estimates lifetime savings of $324,489 per patient treated. If those numbers hold outside the model, MORE would rank among the most cost-effective addiction interventions ever priced — two to six times more efficient than the treatment approaches the U.S. system currently pays for at scale.

What the Numbers Actually Say

Wilson, who directs the Matheson Center for Health Care Studies at the University of Utah School of Medicine, built the evaluation on top of existing clinical trial data rather than running a new experiment. The method matters: economic evaluations ask a different question than clinical trials. A trial asks whether a therapy works; an economic evaluation asks what society gets back, in dollars, when it pays for the therapy — averted hospitalizations, avoided overdoses, fewer arrests, restored earnings.

By that accounting, MORE's benefit-to-cost ratio came out at 12-to-1. The comparison set, drawn from prior published estimates, is sobering for the status quo:

Treatment approach	Benefit-to-cost ratio
Comprehensive case management	1.8-to-1
Residential treatment	2-to-1 to 4.8-to-1
Intensive outpatient treatment	5.1-to-1
MORE (this analysis)	12-to-1

The savings, the authors say, flow from reductions across the major harm categories of opioid misuse: health care utilization, criminal justice involvement, lost productivity, and overdose mortality. "The cost of implementing MORE is small, and its potential payoff in averting misuse and risk of opioid use disorder is very large," Wilson said.

A Therapy Built for Two Problems at Once

MORE was developed by Eric Garland, formerly a distinguished professor and associate dean for research at Utah's College of Social Work and now a professor of psychiatry at UC San Diego School of Medicine. Its design premise is that opioid misuse rarely travels alone — it is usually entangled with chronic pain and emotional distress, and treating any one of the three in isolation tends to fail.

The therapy braids together three skill sets. Mindfulness training teaches patients to regulate craving and pain sensations without reflexively reaching for a pill. Cognitive reappraisal gives them tools to reframe stress and negative emotion. The third component, savoring, is the most distinctive: patients practice reconnecting with naturally rewarding experiences — a walk, a meal, a conversation — on the theory that addiction hijacks the brain's reward circuitry and recovery requires rebuilding sensitivity to ordinary pleasure.

That third element is what separates MORE from generic mindfulness programs. The target population is not abstract "people with addiction" but the much larger group one step upstream: adults with chronic pain who are beginning to misuse prescribed opioids, the exact population from which new cases of opioid use disorder are recruited.

The Clinical Foundation Underneath the Economics

Economic models are only as credible as the trial data feeding them, and MORE's foundation is unusually deep for a behavioral intervention. The therapy has now been tested in more than 16 randomized clinical trials involving over 2,500 participants.

The pivotal study for this analysis was a randomized trial of 250 adults with chronic pain who were misusing prescription opioids, published in JAMA Internal Medicine. Patients receiving MORE reduced opioid misuse by 45% — and the benefits extended to pain symptoms and opioid dosing. Companion neuroimaging work published in JAMA Psychiatry found the therapy strengthened the brain's responses to positive, healthy experiences, providing a plausible biological mechanism for the craving reductions rather than relying on self-report alone.

Why the brain data matters

Addiction medicine has a long history of interventions that work in surveys and fail in the scanner. The neuroimaging evidence moves MORE out of that suspect category: if savoring practice measurably restores reward-circuit response to natural pleasures, the behavioral effects have a mechanism that can be tracked, replicated, and refined — not just attributed to therapist charisma or trial enthusiasm.

The Catch: Models Are Not Reality

A 12-to-1 return deserves scrutiny, and some caveats are built into the genre. Economic evaluations extrapolate trial effects — often measured over months — across decades of modeled lifetime outcomes. They assume implementation quality matches the trial's, that effects don't decay faster than expected, and that the comparison estimates borrowed from older studies remain valid. The per-patient savings figure, $324,489, is a modeled lifetime number, not a bank transfer anyone will ever see.

There is also an implementation gap between a university trial and a Medicaid clinic. MORE requires trained facilitators, typically delivered in group sessions over eight weeks. The therapist workforce for specialized behavioral therapies is thin precisely in the rural and safety-net settings where opioid misuse is most concentrated. And because the analysis focuses on people misusing prescribed opioids — many of whom have not yet developed severe opioid use disorder — its returns may not generalize to patients with long-standing, fentanyl-era addiction, where medication-based treatment remains the evidence-backed standard.

Who Paid for This, and What They Stand to Gain

Transparency deserves a paragraph of its own. The research was funded in part by the National Institute on Drug Abuse through three grants, and the authors declare no competing interests beyond one worth naming: Garland is the founder of the MORE Science Institute, which exists to advance the therapy he invented. That does not invalidate an economic model built on randomized trial data, and the lead author here is Wilson — a health economist, not the therapy's developer. But readers should know the therapy's creator is among its most prominent champions, as is almost always the case when a branded intervention makes the leap from lab to policy pitch.

The $4 trillion epidemic-cost figure anchoring the analysis comes from an Avalere Health white paper, an advisory firm's estimate rather than a government accounting. Even if the true figure is half that, the arithmetic of the argument barely changes: at the scale of American opioid spending, an intervention that plausibly pays back multiples of its cost deserves a serious implementation test.

Why Cost-Effectiveness Is Suddenly the Argument That Matters

The timing of this paper is not accidental. Federal and state budgets for addiction services are under visible strain — grant terminations, tightened harm reduction funding rules, and settlement dollars being fought over by every level of government. In that environment, the interventions that survive are the ones that can argue their way into a budget line.

Garland frames the ambition accordingly: he wants MORE embedded not just in addiction specialty clinics but "upstream in primary care, where we have a chance to intervene before opioid misuse progresses to more severe addiction." Primary care is where the 250-patient trial's population actually lives — people with back pain, arthritis, post-surgical prescriptions, and a slowly escalating relationship with their medication. Catching misuse there is cheaper than treating disorder later by almost any accounting, which is precisely the point the Value in Health paper is built to prove.

What Scaling Would Actually Require

Turning a favorable benefit-to-cost ratio into routine care takes more than a journal publication. Insurers would need billing codes and reimbursement rates that make group-based mindfulness therapy worth a clinic's while. Health systems would need training pipelines — MORE is manualized, which helps, but facilitator certification still takes time and money. And someone would need to run the unglamorous implementation trials showing the therapy works when delivered by ordinary clinicians to ordinary patients, not by the lab that invented it.

None of that diminishes the finding. At a moment when the policy conversation around opioids oscillates between enforcement and retrenchment, the Utah analysis offers a third frame: some interventions pay for themselves many times over, and the cheapest point of intervention is before the crisis. Whether payers and legislatures act on that arithmetic is, as always, the harder trial.